Regulatory approval of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) , MHRA (updated 19th July 2021)

Information for healthcare professionals and the public about Vaxzevria (previously COVID-19 Vaccine AstraZeneca). 19 July 2021 Added Lay summary, Vaxzevria (previously COVID‑19 Vaccine AstraZeneca, suspension for injection) COVID-19 Vaccine (ChAdOx1‑S [recombinant]) 16 July 2021 Updated to reflect the addition of capillary leak syndrome a s a contraindication. Also changed the name of the COVID-19 Vaccine AstraZeneca in the Conditional Marketing Authorisation product information to the brand name - Vaxzevria.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news